Cargando…

Combination of the LARS1 Inhibitor, BC-LI-0186 with a MEK1/2 Inhibitor Enhances the Anti-Tumor Effect in Non–Small Cell Lung Cancer

PURPOSE: The mammalian target of rapamycin complex 1 (mTORC1) regulates cell growth and proliferation by growth factor coordination and amino acid availability. Leucyl-tRNA synthetase 1 (LARS1) senses the intracellular leucine concentration and mediates amino acid-induced activation of mTORC1. Thus,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Sang Hoon, Kim, Eun Young, Han, Jung Min, Han, Gyoonhee, Chang, Yoon Soo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Cancer Association 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372589/ https://www.ncbi.nlm.nih.gov/pubmed/36960627 http://dx.doi.org/10.4143/crt.2022.1527

Ejemplares similares

Therapeutic effects of the novel Leucyl-tRNA synthetase inhibitor BC-LI-0186 in non-small cell lung cancer
por: Kim, Eun Young, et al.
Publicado: (2019)

MEK inhibitors for the treatment of non-small cell lung cancer
por: Han, Jing, et al.
Publicado: (2021)

EHMTI-0186. Multi-center 3T MRI study of cortical thickness abnormalities in migraine
por: Magon, S, et al.
Publicado: (2014)

Discovery of > 160GeV gamma-rays from 1ES 1101-232 (z=0.186) with H.E.S.S.
por: Tluczykont, M
Publicado: (2005)

Discovery of Novel AKT Inhibitors with Enhanced Anti-Tumor Effects in Combination with the MEK Inhibitor
por: Dumble, Melissa, et al.
Publicado: (2014)

Anti-Melanoma Activities of Haspin Inhibitor CHR-6494 Deployed as a Single Agent or in a Synergistic Combination with MEK Inhibitor
por: Han, Lili, et al.
Publicado: (2017)

Triplet Therapy in Melanoma — Combined BRAF/MEK Inhibitors and Anti-PD-(L)1 Antibodies
por: Dixon-Douglas, Julia R., et al.
Publicado: (2022)

Impact of MEK Inhibitor Therapy on Neurocognitive Functioning in NF1
por: Walsh, Karin S., et al.
Publicado: (2021)

Cellular and Molecular Mechanisms of MEK1 Inhibitor–Induced Cardiotoxicity
por: Beck, Tyler C., et al.
Publicado: (2022)

BMI1-Inhibitor PTC596 in Combination with MCL1 Inhibitor S63845 or MEK Inhibitor Trametinib in the Treatment of Acute Leukemia
por: Seipel, Katja, et al.
Publicado: (2021)

The small molecule Mek1/2 inhibitor U0126 disrupts the chordamesoderm to notochord transition in zebrafish
por: Hawkins, Thomas A, et al.
Publicado: (2008)

RIP1 protects melanoma cells from apoptosis induced by BRAF/MEK inhibitors
por: Lei, Fu Xi, et al.
Publicado: (2018)

MEK and the inhibitors: from bench to bedside
por: Akinleye, Akintunde, et al.
Publicado: (2013)

Current Development Status of MEK Inhibitors
por: Cheng, Ying, et al.
Publicado: (2017)

HIV-1 CRF08_BC mutants resistant to reverse transcriptase inhibitors
por: Wu, Hao, et al.
Publicado: (2014)

Natural Compound-Derived Cytochrome bc1 Complex Inhibitors as Antifungal Agents
por: Musso, Loana, et al.
Publicado: (2020)

Identification and Characterization of a Novel Chemotype MEK Inhibitor Able to Alter the Phosphorylation State of MEK1/2
por: Yoshida, Takayuki, et al.
Publicado: (2012)

Induction of immunoglobulin transcription factor 2 and resistance to MEK inhibitor in melanoma cells
por: Hur, Eun-Hye, et al.
Publicado: (2017)

Pharmacokinetics and tolerability of the dual TORC1/2 inhibitor sapanisertib in combination with the MEK inhibitor trametinib in dogs
por: Wei, Bih-Rong, et al.
Publicado: (2022)

MEK inhibitors against MET-amplified non-small cell lung cancer
por: Chiba, Masato, et al.
Publicado: (2016)

The newly identified MEK1 tyrosine phosphorylation target MACC1 is druggable by approved MEK1 inhibitors to restrict colorectal cancer metastasis
por: Kobelt, Dennis, et al.
Publicado: (2021)

Correction to: RIP1 protects melanoma cells from apoptosis induced by BRAF/MEK inhibitors
por: Lei, Fu Xi, et al.
Publicado: (2019)

Combined Therapy with Anti-PD1 and BRAF and/or MEK Inhibitor for Advanced Melanoma: A Multicenter Cohort Study
por: Huynh, Sandra, et al.
Publicado: (2020)

MEK Inhibitor PD-0325901 Overcomes Resistance to CK2 Inhibitor CX-4945 and Exhibits Anti-Tumor Activity in Head and Neck Cancer
por: Bian, Yansong, et al.
Publicado: (2015)

Search for Novel Lead Inhibitors of Yeast Cytochrome bc1, from Drugbank and COCONUT
por: Jović, Ozren, et al.
Publicado: (2021)

IDF21-0186 Real-world effectiveness of Diabefly digital therapeutics program for glycemic control during COVID-19 pandemic in India
por: Verma, R., et al.
Publicado: (2022)

CRISPR/Cas9 Edited RAS & MEK Mutant Cells Acquire BRAF and MEK Inhibitor Resistance with MEK1 Q56P Restoring Sensitivity to MEK/BRAF Inhibitor Combo and KRAS G13D Gaining Sensitivity to Immunotherapy
por: Turner, Elizabeth, et al.
Publicado: (2022)

Commissioning the Phase-1 LAr Upgrade
por: Kay, Ellis
Publicado: (2021)

Commissioning the Phase-1 LAr Upgrade
por: Kay, Ellis
Publicado: (2021)

MEK inhibitors for the treatment of NRAS mutant melanoma
por: Sarkisian, Saro, et al.
Publicado: (2018)

The Use of MEK Inhibitors in Neurofibromatosis Type 1–Associated Tumors and Management of Toxicities
por: Klesse, Laura J., et al.
Publicado: (2020)

A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor
por: Bendell, Johanna C, et al.
Publicado: (2017)

Experimental treatment of NRAS-mutated neurocutaneous melanocytosis with MEK162, a MEK-inhibitor
por: Küsters-Vandevelde, Heidi VN, et al.
Publicado: (2014)

Structure and calibration of the H1 LAR calorimeter and the novel TGT concept for LAR calorimetry at the LHC
por: Braunschweig, W
Publicado: (1995)

Targeting immune-checkpoint inhibitor resistance mechanisms by MEK inhibitor and agonist anti-CD40 antibody combination therapy
por: Baumann, Daniel, et al.
Publicado: (2020)

Response to MEK inhibitor in small cell neuroendocrine carcinoma of the cervix with a KRAS mutation
por: Lyons, Yasmin A., et al.
Publicado: (2014)

Antigen Peptide Transporter 1 (TAP1) Promotes Resistance to MEK Inhibitors in Pancreatic Cancers
por: Li, Boya, et al.
Publicado: (2022)

Characterization of thraustochytrid-specific sterol O-acyltransferase: modification of DGAT2-like enzyme to increase the sterol production in Aurantiochytrium limacinum mh0186
por: Ishibashi, Yohei, et al.
Publicado: (2023)

Histone deacetylase inhibitors: a promising partner for MEK inhibitors in uveal melanoma?
por: Faião-Flores, Fernanda, et al.
Publicado: (2019)

Diarrhea and colitis related to immune checkpoint inhibitor and BRAF/MEK inhibitor therapy
por: Kuang, Andrew G., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_dfsfdemv4m8kq2kinsdlk2c2bi